Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14285929 | 0.86 | ALDH1A3 (0.52) | ALDH1A3ERN1FFAR4ALDH1A1KMT2A | |
| SCHEMBL20237750 | 0.84 | DRD1 (0.49) | ERN1ALDH1A1KMT2AHPGDNFE2L2 | |
| SCHEMBL29668957 | 0.84 | DRD1 (0.49) | ERN1ALDH1A1KMT2AHPGDNFE2L2 | |
| SCHEMBL24530453 | 0.83 | ALDH1A3 (0.57) | ALDH1A3ERN1ALDH1A1KMT2APARP10 | |
| SCHEMBL14689988 | 0.83 | ALDH1A3 (0.42) | ALDH1A3ERN1FFAR4ALDH1A1 | |
| SCHEMBL6932787 | 0.82 | ALDH1A1 (0.40) | ALDH1A3FFAR4ALDH1A1KMT2APARP10 | |
| SCHEMBL2599795 | 0.82 | FFAR4 (0.47) | ALDH1A3ERN1FFAR4 | |
| SCHEMBL2599711 | 0.81 | ALDH1A3 (0.44) | ALDH1A3ERN1FFAR4ALDH1A1KMT2A | |
| SCHEMBL6930848 | 0.80 | ALDH1A3 (0.53) | ALDH1A3ERN1FFAR4ALDH1A1KMT2A | |
| SCHEMBL387186 | 0.79 | ERN1 (0.61) | ERN1ALDH1A1KDM4ENFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371657-A1 | Transition-metal complexes and use thereof in transition-metal catalysed reactions.. | Bayer Aktiengesellschaft (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030220512-A1 | Novel transition metal complexes and their use in transition metal-catalysed reactions | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220512-A1 | Novel transition metal complexes and their use in transition metal-catalysed reactions | AP1M1, AP3M1, CYC1 | ALDH1A3 3225/4885ERN1 1660/4885FFAR4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.